OptiNose, Inc.
http://www.optinose.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OptiNose, Inc.
Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
Optinose Looking For A Partner To Optimize Big Opportunity In Chronic Sinusitis
With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
- Other Names / Subsidiaries
-
- OptiNose AS
- OptiNose UK Ltd.
- OptiNose US, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice